A phase I study of Ad-RTS-mIL-12 + veledimex in pediatric brain tumors, including diffuse intrinsic pontine glioma (DIPG)

Trial Profile

A phase I study of Ad-RTS-mIL-12 + veledimex in pediatric brain tumors, including diffuse intrinsic pontine glioma (DIPG)

Planning
Phase of Trial: Phase I

Latest Information Update: 01 May 2017

At a glance

  • Drugs INXN 2001 (Primary) ; Veledimex (Primary)
  • Indications Brain cancer; Glioma
  • Focus Adverse reactions
  • Most Recent Events

    • 01 May 2017 According to a ZIOPHARM Oncology media release, the company plans to initiate this study in first half 2017.
    • 20 Feb 2017 New trial record
    • 16 Feb 2017 According to a ZIOPHARM Oncology media release, the company plans to initiate this study in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top